These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 17697909)

  • 1. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
    Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y;
    Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
    Taher A; Al Jefri A; Elalfy MS; Al Zir K; Daar S; Rofail D; Baladi JF; Habr D; Kriemler-Krahn U; El-Beshlawy A
    Acta Haematol; 2010; 123(4):220-5. PubMed ID: 20424435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
    Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J; Tolley K; Vieira J; Chandiwana D
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
    Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J
    Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.